Pre-erythrocytic malaria vaccines: identifying the targets.

Patrick E. Duffy, Tejram Sahu, Adovi Akue, Neta Milman, Charles Anderson

Research output: Contribution to journalReview articlepeer-review

50 Scopus citations


Pre-erythrocytic malaria vaccines target Plasmodium during its sporozoite and liver stages, and can prevent progression to blood-stage disease, which causes a million deaths each year. Whole organism sporozoite vaccines induce sterile immunity in animals and humans and guide subunit vaccine development. A recombinant protein-in-adjuvant pre-erythrocytic vaccine called RTS,S reduces clinical malaria without preventing infection in field studies and additional antigens may be required to achieve sterile immunity. Although few vaccine antigens have progressed to human testing, new insights into parasite biology, expression profiles and immunobiology have offered new targets for intervention. Future advances require human trials of additional antigens, as well as platforms to induce the durable antibody and cellular responses including CD8(+) T cells that contribute to sterile protection.

Original languageEnglish (US)
Pages (from-to)1261-1280
Number of pages20
JournalExpert review of vaccines
Issue number10
StatePublished - Oct 2012
Externally publishedYes

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Pre-erythrocytic malaria vaccines: identifying the targets.'. Together they form a unique fingerprint.

Cite this